OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis

Article2019

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

Pieter Sonneveld, Annemiek Broijl, Francesca Gay, Mario Boccadoro, Hermann Einsele, Joan Bladé, Meletios A Dimopoulos, Michel Delforge, Andrew Spencer, Roman Hájek, Fredrik Schjesvold, Sarah Lonergan, Elena Smith, Robin Carson, Wendy Crist, Wendy Garvin, Jessica Vermeulen, Philippe Moreau

Article2024

P-368 Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, ,

Article2024

P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

Salomon Manier, Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksaç, Thierry Façon

Article2024

OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

Thierry Façon, Meletios A Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, T. John Martin, Salomon Manier, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, Robert Z. Orlowski

Article2024

Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).

Thierry Façon, Meletios A Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Špıčka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, Robert Z. Orlowski

Discussion(0)

Related publications

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

P-368 Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).